Established in 2021 by researchers from the Manchester Institute of Biotechnology, Imperagen is a pioneering techbio company, focused on accelerating the process of enzyme engineering. Serving diverse markets, from pharmaceutical manufacturing and life sciences to sustainable fine chemical production and industrial applications, we work hand-in-hand with our customers to de-risk and streamline their product development and fast track their path to market.
Imperagen: Venture Capital Funding History
Imperagen
Imperagen
- Life Sciences
- Manchester, United Kingdom
- £5m
- imperagen.com
- Update Information
More venture news
- 23 Sept 2026

Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences - 18 Sept 2026

Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026

Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences
